Release Date: May 20, 2015 | Expiration Date: May 20, 2016
Media: Print with online posttest, evaluation, and request for credit
This activity is designed to aid physicians in assessing new data in the neoadjuvant treatment of breast cancer, including patient-specific treatment regimens and monitoring for adverse events during therapy, and applying these data to their practices.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists who manage and treat patients with breast cancer. Surgical oncologists, radiation oncologists, pathologists, fellows, nurses, nurse practitioners, physician assistants, and other health care providers interested in the treatment of breast cancer are also invited to participate.
Learning ObjectivesAfter participating in this CME activity, learners should be better prepared to:
- Identify predictors of recurrence in patients who receive treatment in the neoadjuvant setting for breast cancer
- Describe the role of pathologic complete response in evaluating the effectiveness of agents in patients with breast cancer in the neoadjuvant setting
- Identify tumor subtypes in which pathologic complete response rate can be a predictor of disease recurrence in patients with breast cancer who receive neoadjuvant treatments
Allison A. Muller, PharmD, DABAT
Disclosure: No relevant financial relationships with commercial interests to disclose.
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, Oncoplex Diagnostics, Merck, and Novartis.
Myron Czuczman, MD
Professor of Oncology
Chief, Lymphoma/Myeloma Service
Department of Medicine
Head, Lymphoma Translational Research Laboratory
Department of Immunology
Roswell Park Cancer Institute
Disclosure: Other support: Advisory Board: Algeta, Celgene Corporation, Teva, Boehringer Ingelheim, Mundipharma.
FacultyAdam Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/Oncology Director, Comprehensive Breast Cancer Center
University of Pittsburgh School of Medicine
Disclosure: Grant/Research Support: Novartis; Consultant: Novartis.
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians' Education Resource (PER®), LLC (Ann C. Lichti, CHCP, Michael Perlmutter, PharmD, MS, and Kerry Clayton) as well as the editorial staff of The American Journal of Hematology/Oncology (Devera Pine) have no relevant financial relationships with commercial interests to disclose.
In accordance with Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial SupportSM, PER® resolved all conflicts of interest (COI) prior to the release of this CME activity using a multistep process.
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is funded by Physicians' Education Resource®.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
DisclaimerThe opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Hardware And Software RequirementsSupported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise